Page 1511 - Williams Hematology ( PDFDrive )

1486 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1487

757. Olavarria E, Kanfer E, Szydlo R, et al: Early detection of BCR-ABL transcripts by 787. Griesshammer M, Heinze B, Bangerter M, et al: Karyotype abnormalities and their
quantitative reverse transcriptase-polymerase chain reaction predicts outcome after clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med 75:8836,
allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97:1560, 1997.
2001. 788. Spencer A, Vulliamy T, Kaeda J, et al: Clonal instability preceding lymphoid blastic
758. Radich JP, Gooley T, Bryant E, et al: The significance of bcr-abl molecular detection transformation of chronic myeloid leukemia. Leukemia 11:195, 1997.
in chronic myeloid leukemia patients “late” 18 months or more after transplantation. 789. Anastasi J, Feng J, LeBeau MM, et al: The relationship between secondary chromo-
Blood 98:1701, 2001. somal abnormalities and blast transformation in chronic myelogenous leukemia.
759. Lion T: Minimal residual disease. Curr Opin Hematol 6:406, 1999. Leukemia 9:628, 1995.
760. Thiele J, Wickenhauser C, Kvasnicka HM, et al: Mixed chimerism of bone marrow 790. Bartram CR, de Klein A, Hagemeijer A, et al: Additional C-abl/bcr rearrangements in
CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation a CML patient exhibiting two Ph1 chromosomes during blast crisis. Leuk Res 10:221,
for chronic myelogenous leukemia. Transplantation 74:982, 2002. 1986.
761. Sobrinho-Simões M, Wilczek V, Score J, et al: In search of the original leukemic clone 791. Collins SJ, Grudine MT: Chronic myelogenous leukemia: Amplification of a rear-
in chronic myeloid leukemia paients in complete molecular remission after stem cell ranged c-abl oncogene in both chronic phase and blast crisis. Blood 69:893, 1987.
transplantation or imatinib. Blood 116:1329, 2010. 792. Mughal TI, Goldman JM: Chronic myeloid leukemia: Why does it evolve from
762. Jabbour E, Kantarjian HM, O’Brien S, et al: Front-line therapy with second-generation chronic phase to blast transformation? Front Biosci 11:198, 2006.
tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leuke- 793. Schaefer-Rego K, Dudek H, Popenoe D, et al: CML patients in blast crisis have break-
mia: What is the optimal response? J Clin Oncol 29:4260, 2011. points localized to a specific region of the bcr. Blood 70:448, 1987.
763. Kantarjian HM, Shan J, Jones D et al: Significance of increasing levels of minimal 794. Mills KI, Benn P, Birnie GD: Does the breakpoint within the major breakpoint region
residual disease in patients with Philadelphia chromosome-positive chronic myeloge- (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An
nous leukemia in complete cytogenetic response. J Clin Oncol 27:3659, 2009. analytical comparison of current literature. Blood 78:1155, 1991.
764. Branford S, Kim DW, Soverini S, et al: Initial molecular response at 3 months may 795. Bartram CR, Janssen JWG, Becher R, et al: Persistence of chronic myelocytic leukemia
predict both response and event-free survival at 24 months in imatinib-resistant or despite deletion of rearranged bcr/c-abl sequences in blast crisis. J Exp Med 164:1389,
-intolerant patients with Philadelphia chromosome-positive chronic myeloid leuke- 1986.
mia in chronic phase treated with nilotinib. J Clin Oncol 30:4323, 2012. 796. Okabe M, Matsushima S: Philadelphia chromosome-positive leukemia: Molecular
765. Radich JP: How I monitor residual disease in chronic myeloid leukemia. Blood analysis of bcr and abl genes and transforming genes. Nippon Ketsueki Gakkai Zasshi
114:3376, 2009. 51:1471, 1988.
766. Branford S, Yeung DT, Prime JA, et al: BCR-ABL1 doubling times more reliably assess 797. Ahuja H, Bar-Eli M, Arlin Z, et al: The spectrum of molecular alterations in the evo-
the dynamics of CML relapse compared with the BCR-ABL1 fold rise: Implications for lution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991.
monitoring and management. Blood 119:4264, 2012. 798. Kelman Z, Prokocimer M, Peller S, et al: Rearrangements in the p53 gene in Philadel-
767. Giles FJ, Cortes JE, Kantarjian HM, O’Brien S: Accelerated and blastic phase of phia chromosome positive chronic myelogenous leukemia. Blood 74:2318, 1989.
chronic myelogenous leukemia. Hematol Oncol Clin North Am 18:753, 2004. 799. Mashal R, Shtalrid M, Talpaz M, et al: Rearrangement and expression of p53 in the
768. Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A chronic phase and blast crisis of chronic myelocytic leukemia. Blood 75:180, 1990.
concise update. Blood 82:691, 1993. 800. Guinn BA, Mello KI: P53 mutations, methylation and genomic instability in the pro-
769. Swerdlow SH, Campo E, Harris NL, et al: World Health Organization Classification of gression of chronic myeloid leukemia. Leuk Lymphoma 26:241, 1997.
Tumours of Haematopoieitc and Lymphoid Tissues. IARC Press, Lyon, 2008. 801. Malinen T, Palotie A, Pakkala S, et al: Acceleration of chronic myeloid leukemia cor-
770. Druker BJ: Chronic myelogenous leukemia, in Principles & Practice of Oncology, vol 2, relates with calcitonin gene methylation. Blood 77:2435, 1991.
ed 8, edited by DeVita VT, Lawrence TS, Rosenburg SA, p 2267. Lippincott, Williams 802. Asimakopoolos FA, Shteper PJ, Krichevsky S, et al: ABL1 methylation is a distinct
and Wilkins, Baltimore, MD, 2007. molecular event associated with clonal evolution of chronic myeloid leukemia. Blood
771. Bolton-Gillespie E, Schemionek M, Klein HU, et al: Genomic instability may origi- 94:2452, 1999.
nate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121:4175, 803. Towatari M, Adachi K, Kato H, Saito H: Absence of the human retinoblastoma gene
2013. product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 78:
772. Jamieson CH, Ailles LE, Dylla SJ, et al: Granulocyte-macrophage progenitors as can- 2178, 1991.
didate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657, 2004. 804. Sill H, Goldman JM, Cross NC: Homozygous deletions of the p16 tumor-suppressor
773. Michor F: Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood
25:1114, 2007. 85:2013, 1995.
774. Wodarz D: Stem cell regulation and the development of blast crisis in chronic myeloid 805. Hernandez-Boluda JC, Cervantes F, Colomer D, et al: Genomic p16 abnormalities in
leukemia: Implications for the outcome of Imatinib treatment and discontinuation. the progression of chronic myeloid leukemia into blast crisis. Exp Hematol 31:204,
Med Hypotheses 70:128, 2008. 2003.
775. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in 806. Serra A, Gottardi E, Della Ragione F, et al: Involvement at the cyclin-dependent
human cancer. Nat Rev Cancer 7:441, 2007. kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of
776. Brazma D, Grace C, Howard J, et al: Genomic profile of chronic myelogenous leu- chronic myelogenous leukaemia. Br J Haematol 91:625, 1995.
kemia: Imbalances associated with disease progression. Genes Chromosomes Cancer 807. Menssen HD, Renkl HJ, Rodeck U, et al: Presence of Wilms’ tumor gene (wt1)
46:1039, 2007. transcripts and the WT1 nuclear protein in the majority of human acute leukemias.
777. Gaiger A, Henn T, Horth E, et al: Increase of bcr/abl chimeric mRNA expression in Leukemia 9:1060, 1995.
tumor cells of patients with chronic myeloid leukemia precedes disease progression. 808. Mitarri K, Ogawa S, Tanaka T, et al: Generation of the AML1-EVI-1 fusion gene in the
Blood 86:2371, 1995. t(3;21) (q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 13:504,
778. Elmaaglacli AH, Beelen DW, Opalka B, et al: The amount of BCR/ABL fusion tran- 1994.
scripts detected by real-time quantitative polymerase chain reaction method in 809. Carapeti M, Goldman JM, Cross NC: Overexpression of EV-l in blast crisis of chronic
patients with Philadelphia chromosome positive chronic myeloid leukemia disease myeloid leukemia. Leukemia 10:1561, 1996.
stages correlates with the disease stages. Ann Hematol 79:424, 2000. 810. Mori N, Takeuchi S, Tasaka T, et al: Absence of microsatellite instability during the
779. Lowenberg B, Hagemeijer A, Swart K, Abels J: Serial follow-up of patients with progression of chronic myelocytic leukemia. Leukemia 11:151, 1997.
chronic myeloid leukemia (CML) with combined cytogenetic and colony culture 811. Handa H, Hegde UP, Kuteninikov VM, et al: Bcl-2 and c-myc expressions, cell cycle
methods. Exp Hematol 10:123, 1982. kinetics and apoptosis during the progression of chronic myelogenous leukemia from
780. Haas OA, Schwarzmeier JD, Nachera E, et al: Investigations on karyotype evolution in diagnosis to blastic phase. Leuk Res 21:479, 1997.
patients with chronic myeloid leukemia (CML). Blut 48:33, 1984. 812. Daheron L, Salmeron S, Patri S, et al: Identification of several genes differentially
781. Swolin B, Weinfeld A, Westin J, et al: Karyotypic evolution in Ph-positive chronic expressed during progression of chronic myelogenous leukemia. Leukemia 12:326,
myeloid leukemia in relation to management and disease progression. Cancer Genet 1998.
Cytogenet 18:65, 1985. 813. Foti A, Ahuja HG, Allen SL, et al: Correlation between molecular and clinical events
782. Cortes J, O’Dwyer ME: Clonal evolution in chronic myelogenous leukemia. Hematol in the evolution of chronic myelocytic leukemia to blast crisis. Blood 77:2441, 1991.
Oncol Clin North Am 18:671, 2004. 814. Mori N, Morosetti R, Loe S, et al: Allelotype analysis in the evolution of chronic mye-
783. Honda H, Ushijima K, Oda H, et al: Acquired loss of p53 induces blast transformation locytic leukemia. Blood 90:2010, 1997.
in p210bcr/abl-expressing hematopoietic cells: A transgenic study for blast crisis in 815. Hehlmann R: How I treat CML blast crisis. Blood 120:737, 2012.
human CML. Blood 95:1144, 2000. 816. Radich JP, Dai H, Mao M, et al: Gene expression changes associated with progression
784. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K: Mutation of p51/p63 gene is associated and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103:2794, 2006.
with blast crisis in chronic myelogenous leukemia. Leukemia 15:1729, 2001. 817. Yong AS, Szydlo RM, Goldman JM, et al: Molecular profiling of CD34+ cells identifies
785. Coiffier B, Byron PA, Flere D, et al: Chronic granulocytic leukemia: Early detection of low expression of CD7, along with high expression of proteinase 3 or elastase, as pre-
metamorphosis with “in vitro” culture of granulocytic progenitors. Biomedicine 33:96, dictors of longer survival in patients with CML. Blood 107:205, 2006.
1980. 818. Spiers ASD: Metamorphosis of chronic granulocytic leukemia: Diagnosis, classifica-
786. Todd MB, Waldron JA, Jennings TA, et al: Loss of myeloid differentiation antigens pre- tion and management. Br J Haematol 49:1, 1979.
cedes blastic transformation in chronic myelogenous leukemia. Blood 70:122, 1987. 819. Grignani F: Chronic myelogenous leukemia. Crit Rev Oncol Hematol 4:31, 1985.

Kaushansky_chapter 89_p1437-1490.indd 1486 9/18/15 3:42 PM